Cannabis

View Systems, Inc.’s (VSYM) Sannabis Provides Update on their Hemp Operations in Uruguay and Colombia to Supply the World with Hemp Products.

Published

5 years ago

December 10, 2019

GlobeNewswire

Company files quarterly report with the SEC.

Barranquilla, Colombia, Dec. 10, 2019 (GLOBE NEWSWIRE) — View Systems, Inc.’s (VSYM), medical marijuana and hemp subsidiary, Sannabis S.A.S. (“the Company”) provides an update on their hemp operations in Colombia and Uruguay. Sannabis aims to become a reliable supplier to Hemp companies from around the World seeking to penetrate their local markets.

Colombia

Sannabis is a pioneer in the hemp/medical marijuana space in Colombia since 2014 through their indigenous partners and was a significant part of the legalization movement for over 20 years, even assisting in the drafting of medical marijuana legislation under former President Santos. They have since applied for a transformation license to convert non-psychoactive cannabis into finished products and by-products and are now preparing for a site visit from the agency in charge of issuing that license. Sannabis and its affiliates have also applied for the coveted Seed Bank License and Cultivation License, right now greenhouses are being built at their new facility where they moved their seed bank as they await a site visit from ICA (Agriculture Department). The Seed Bank application is a tremendous advantage since no more applications are being accepted.

Sannabis recently leased a new farm and moved the Seed Bank to be closer to their University partner where they intend to patent strains and develop other products. They’ve already effectively tested a hemp roof tile that is part of a much bigger bio-construction project that has initiated with multi-national organizations and universities that will be announced later. Not only did they perfect the hemp roof tile, but they also contributed to the project a custom-made hemp brick maker they developed. While they await their licenses, Sannabis is currently producing a line of topical creams, ointments, and oils to be sold directly to consumers in Colombia, the launch with the first 500 direct marketers is scheduled for March 2020. Although these products are new, some of the formulas are the same Sannabis has used for years with positive results in Colombia, all-natural plant-based ingredients with a bee’s wax or olive oil base. These innovative new products all have health registrations with INVIMA, Colombia’s Health Authority. For pictures of their new product lines, please visit https://drive.google.com/open?id=1ElYQYQyVFOhWywPapodJOig-UfJunGJR

Sannabis.co website is being updated with new marketing material and technical specifications of these new products. Sannabis will not only transform material grown by them and other legal growers in Colombia, but also transform raw material legally imported into Colombia from countries where legal. For a timeline of Sannabis’ progression, visit https://www.sannabis.co/taller-libre. To view a video history of Sannabis, visit https://youtu.be/GIf75LAayos

Uruguay

Sannabis owns a significant equity position in a one of the few licensed growers in Uruguay and is financing operations there. Company management was in Uruguay last month to oversee the importation of hemp seeds and subsequent planting. They purchased nutrients by the tonne to prepare their hemp fields for planting next week, this harvest will be ready in March/April 2020 and will generate a combination of hemp seeds and biomass to produce CBD in bulk. The seeds they’re planting can produce 10-12 Tonnes (22-24,000 pounds) of Hemp Biomass per hectare, they’re planting about 7-8 hectares now for a total of approximately 150,000 pounds of Biomass in the next 4 months. About 1 tonne per hectare of hemp seeds with high oil content can be achieved along with a high fiber content in the stem.

While in Uruguay management met with local accredited investors with influence to apply for a transformation license in a free trade zone giving them access to the much bigger markets of Argentina and Brazil. They also met with a qualified professional to assist with this transformation license application and distribution of their Colombian products in Uruguay.

Raw hemp flower, biomass, and seeds from their first harvest next Spring will be exported to countries where it can be legally transformed and sold while they obtain their transformation license in Uruguay. Greenhouses to grow high quality hemp flower for export to the U.S. will be built next month at the farm Sannabis purchased for major expansion. Sannabis works closely with an equity partner in Uruguay, a top law firm, to take advantage of every opportunity and oblige by the law in all jurisdictions their Uruguay operations does business in. Sannabis imported the Futura 75 Hemp seed from Europe which produces significant yields in oil, seeds, fiber, and biomass, but only has .12 % THC, well below the threshold for export to the U.S., Canada, and most countries. Click here for characteristics of Futura 75 posted by an independent vendor, https://www.ihempfarms.com/DS_Futura75

Although Uruguay was the first country in the World to legalize marijuana, its citizens aren’t aware of the medical benefits of the plant since it was primarily legalized for recreational use. Sannabis will use their decades of experience successfully socializing medical marijuana in Colombia to do the same in Uruguay, Argentina, and Brazil. In order to build their brand while they get a transformation license in Uruguay, Sannabis will begin exporting finished products from Colombia under a local brand that will also be sold into Argentina and Brazil.

To see a simple memorialization of the initiation of their Uruguay hemp fields, visit https://drive.google.com/open?id=19UhWtMNkSlGOX5myqylDvroXj1EVttrB.

View Systems, Inc. would also like to announce the filing of their Q3 Quarterly Report with the SEC. The report incorrectly posted the number of shares outstanding, current outstanding common shares as of today are 474,309,727.

About View Systems Inc.

View Systems Inc. provides security and surveillance products to law enforcement facilities such as correctional institutions as well as to government agencies, schools, courthouses, event and sports venues, the military and commercial businesses. View Systems’ products are used by commercial businesses and residential consumers wishing to monitor their assets and limit their liability. For more information, visit www.viewsystems.com

View Systems Inc. (www.viewsystems.com) is the developer of the ViewScan Weapons Detection System, a Department of Homeland Security (DHS) sanctioned product used by law enforcement and correctional facilities, government agencies, schools, courthouses, special events, sports venues, military, and commercial businesses. View Systems acquired Colombian Cannabis company, Sannabis, to diversify into the burgeoning Cannabis industry with new management committed to continue developing their ViewScan Weapons Detection System in Colombia for the local and international market. View Systems intends to file for a name and symbol change in the near future, however, they will continue to develop their newly enhanced state of the art ViewScan products in Barranquilla, Colombia for the local and international markets.

ViewScan is installed at government agencies in Washington, DC and elsewhere, major school systems, correctional facilities, ports, and police stations around the world. View Scan has also been used at events where top security clearance is required for former Presidents. In this Market Survey Report commissioned by the U.S. Department of Homeland Security (DHS), ViewScan demonstrated more features than their top competitors, https://www.dhs.gov/sites/default/files/publications/WTMD-MSR_0614-508.pdf

Company/Media Contact:

View Systems, Inc.
John Campo, President/Chairman
+1-410-236-8200 USA (Office/WhatsApp)
+57-318-657-0918 Colombia (Office)
[email protected]

Cannabis

IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

Published

1 day ago

September 11, 2024

CISION (PR Newswire)

im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors

TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.

“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”

Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.

“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”

Arbel holds a BA and MBA from Tel Aviv University.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.

Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, CEO
IM Cannabis Corp.
[email protected]

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html

Cannabis

One World Products Issues Shareholder Update Letter

Published

1 day ago

September 11, 2024

GlobeNewswire

Cannabis

Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape

Published

2 weeks ago

August 29, 2024

GlobeNewswire

Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.

The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:

Derivatives;
Source;
Application;
Route of Administration;
End-user;
Distribution Channel; and
Country.

Market Highlights Identified in the Report

Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.

The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.

Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.

Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.

Regional Insights

Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.

Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.

Competitive Landscape

The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.

The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.

Key Topics Covered

Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

A selection of companies mentioned in this report includes, but is not limited to:

Aurora Cannabis Inc.
Bedrocan
Biocann
BIOTA Biosciences LLC
Cannamedical
Mary Jane CBD
Sanity Group GmbH
Tilray
Valcon Medical

For more information about this report visit https://www.researchandmarkets.com/r/dh7q46

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.